Tomasello Shawn
SEC-identified person · CIK 1617239 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| 4D Molecular Therapeutics, Inc. FMDT | Director | filed 2020–2026 |
| Cabaletta Bio, Inc. CABA | Director | filed 2023–2026 |
| Kalaris Therapeutics, Inc. KLRS | Director | filed 2022–2024 |
| Gamida Cell Ltd. GMDA | Director | filed 2022–2024 |
| TCR2 Therapeutics INC. TCRR | Director | filed 2021–2023 |
| Urogen Pharma Ltd. URGN | Director | filed 2019–2021 |
| Principia Biopharma Inc. PRNB | Director | filed 2019–2020 |
| Plasmatech Biopharmaceuticals INC accp.ob | Director | filed 2020–2020 |
| Diplomat Pharmacy, Inc. DPLO | Director | filed 2015–2020 |
| Kite Pharma, Inc. KITE | Chief Commercial Officer | filed 2015–2017 |
| Pharmacyclics INC pcyc | Chief Commercial Officer | filed 2014–2015 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.